Pfizer's Prevenar 13 aced study in younger adults; Endo's 2013 earnings to suffer from Lidoderm generics;

@FiercePharma: J&J's trying to block testimony from ex-FDA chief David Kessler, who calls its Risperdal marketing "deeply troubling." More | Follow @FiercePharma

> Pfizer ($PFE) said its Prevenar 13 vaccine worked as well in adults up to 49 years old as in those 60 to 64 years, helping to expand its application for broader use in Europe. Report

> Endo Health Solutions said its 2013 earnings wouldn't hit market expectations because of a patent settlement allowing generic competition to its pain reliever Lidoderm. Report

> Johnson & Johnson's ($JNJ) Janssen unit opened a new European hub in Belgium, allowing medicines from regional production sites to be shipped to one place for distribution. Report

> The blood cancer drug Revlimid failed to improve cancer therapy when added to a typical chemo regimen, a study found. Report

> Hormone therapy soon after menopause relieves some symptoms in women without increasing their risk of heart disease, a new study found, adding more fuel to the debate over hormone use. Report

> China's Fosun Pharmaceutical is preparing to launch a stock offering raising up to HK $600 million ($77 million). Report

> Trading in Mayne Pharma shares was halted in Australia after media reports that it would be raising money for a $100 million U.S. acquisition. Report

Biotech News

 @FierceBiotech: Merger deal gives generic drugmaker control of troubled BioSante. More | Follow @FierceBiotech

 @JohnCFierce: 2012 Fierce 15 winner Aragon raises $50M for 509 program. That's $88M this year. More | Follow @JohnCFierce

 @RyanMFierce: BioSante goes the way of the M&A. More | Follow @RyanMFierce

> Special Report: 10 Truths (or Fictions) About Virtual Biotech Startups. Report

> Report: Biosimilars team at Teva/Lonza slam the brakes on Rituxan knockoff. Article

> Momenta Pharma options antibody against red meat-related inflammation. Story

Medical Device News

 @FierceMedDev: Alere has reached a deal with the FDA on Dx production, looking to move past May's recall of 800K test kits. More | Follow @FierceMedDev

 @MarkHFierce: Sony may be boosting its involvement in med tech, but investors are worried the company is going down a sinkhole. More | Follow @MarkHFierce

 @DamianFierce: Medtronic's next-gen renal denervation device takes a page from the St. Jude tech Medtronic earlier dismissed. More | Follow @DamianFierce

> Life Technologies, CollabRx, forge molecular Dx data deal. Article

> Judge: BD violated Hologic's patents. News

> Tyrx gains Canadian regualtory nod for antibacterial envelope. Story

Pharma Manufacturing News

> Merck whacking 20% of jobs at Ireland API plant. Story

> New Janssen distribution hub consolidates European supply chain. Article

Vaccines News

> Novartis vaccines unit's future hangs on Bexsero approval. Article

> NIH awards $1.38M to professor for HIV vaccine research. Item

> Merck's Gardasil earns high safety marks. Story

> Flu vaccine manufacturers face steep odds. News

And Finally... Police and regulators around the world have closed 18,000 online pharmacy sites in the largest ever clamp-down on criminal gangs selling unauthorized medicines online. Report

Suggested Articles

How long can one infusion of Gilead CAR-T drug Yescarta continue to help patients with refractory large B-cell lymphoma? Pretty long, Gilead showed.

AbbVie and Roche have been fielding their fair share of questions about how well their fixed-duration regimen of Venclexta and Rituxan could keep chro

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.